TLX1 and acute lymphoblastic leukemia: Compound 10058-F4 treatment decreased the growth of ALL-SIL cells to similar levels regardless of TLX1 expression (Figure 4A), suggesting that augmentation of MYC function is a central mechanism of TLX1 contribution to ALL-SIL cell growth.